by Plus Therapeutics | Dec 4, 2024 | LM
Exciting News: ReSPECT-LM Leptomeningeal Metastases Clinical Trial to be Showcased at SABCS 2024! Mark your calendars! Plus Therapeutics is thrilled to present groundbreaking data from our ReSPECT-LM Phase 1 clinical trial at the 2024 San Antonio Breast Cancer...
by Plus Therapeutics | Dec 3, 2024 | Uncategorized
Plus Therapeutics Expands Strategic Partnership with Telix IsoTherapeutics for Rhenium-186 Radioisotope Supply BREAKING NEWS: Plus Therapeutics is pleased to announce the expansion of our strategic agreement with Telix IsoTherapeutics Group, a move that strengthens...
by Plus Therapeutics | Dec 2, 2024 | LM
Inspiring Metastatic Breast Cancer Story: Marlyn’s Journey with Leptomeningeal Metastases The wait is almost over! This week, we are thrilled to release a brand new patient testimonial from one of our courageous ReSPECT-LM patients. In this powerful video, Marlyn...
by Plus Therapeutics | Nov 28, 2024 | Uncategorized
Thankful for the Oncology Community: Celebrating Patients, Caregivers, and Medical Advancements As we take time to reflect on the progress in the field of oncology, Plus Therapeutics extends our deepest gratitude to the patients, caregivers, and the dedicated medical...
by Plus Therapeutics | Nov 22, 2024 | LM
Plus Therapeutics to Present Positive FORESEE Clinical Trial Data at SNO Annual Meeting in Houston Plus Therapeutics is thrilled to present groundbreaking results from the FORESEE Clinical Trial at the Society for Neuro-Oncology (SNO) Annual Meeting in Houston. The...
Recent Comments